Compare LyondellBasell Industries NV (LYB) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LyondellBasell Industries NV vs Medpace Holdings Inc — how do they compare? LyondellBasell Industries NV trades at $61.25 (market cap $19.60B), while Medpace Holdings Inc trades at $530 (market cap $15.08B). The key difference: LyondellBasell Industries NV is the larger of the two by market cap, and LyondellBasell Industries NV pays a 6.78% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| LYB | MEDP | |
|---|---|---|
Market Cap | $19.60B | $15.08B |
Sector | Basic Materials | Technology |
52-Week High | $82.38 | $620.59 |
52-Week Low | $42.28 | $308.88 |
Enterprise Value | $31.22B | $14.55B |
Dividend Yield | 6.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LyondellBasell (LYB) trades at $61.19, up 3.38% today, with a bullish technical signal and strong analyst consensus price target of $72.56. Recent earnings show volatility with Q1 2026 beating expectations, while Q4 2025 missed. The company maintains positive cash flow and recently announced a $0.69 dividend. Revenue has declined from $50.5B in 2022 to $30.2B in 2025, with net income turning negative at -$745M. News highlights include partnerships for sustainable packaging and anticipation of strong Q2 2026 earnings.
LYB presents a mixed outlook: potential upside exists from expected earnings recovery and strategic shifts toward high-margin polymers, but risks include declining revenue, negative profitability, and high debt. Investors should weigh the bullish analyst sentiment against fundamental challenges in the chemical sector.
MEDP trades at $527.93, down 1.82% on the day, with a neutral technical signal and mixed oscillators. The stock shows strong profitability with a 17.19% net margin and 77.25% ROE, though valuations are elevated with a P/E of 33.22. Recent quarters have consistently beaten EPS estimates, but a class action lawsuit filed in June 2026 adds uncertainty. Revenue is projected to grow to $2.7B in 2026, while cash flow trends improve from negative to positive net cash flow.
The outlook is cautious due to high valuation and legal overhangs, but fundamental strength in earnings and backlog quality provides support. Analyst consensus is mixed with a $497 price target below current levels, indicating limited near-term upside. Key risks include lawsuit outcomes and competitive pressures in the CRO sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
